Contrave is not licensed by the MHRA for any indication in the UK. While the FDA has approved it for chronic weight management, UK clinicians must rely on alternative, licensed therapies for obesity.
Contrave combines an opioid antagonist (naltrexone) with a norepinephrine-dopamine reuptake inhibitor (bupropion) to target both appetite and reward pathways. Liraglutide is a GLP-1 receptor agonist that primarily slows gastric emptying and reduces appetite, whereas orlistat works locally in the gut to inhibit fat absorption.
Bupropion is an antidepressant, but individuals with active major depressive disorder or bipolar disorder should be evaluated carefully. Mood changes, including agitation or suicidal thoughts, have been reported, so close psychiatric monitoring is advised.
Alcohol can increase the risk of liver toxicity and may heighten blood-pressure elevations. Moderate alcohol intake (up to one standard drink per day) is generally acceptable, but excessive consumption should be avoided.
The tablet is usually imprinted with “8/90” on one side and “CONTRAVE” on the other. Specific imprint details may vary by manufacturer, so checking the packaging or pharmacy label is recommended.
Standard workplace drug screens do not test for naltrexone or bupropion. However, specialized testing for these compounds exists and could be requested in certain contexts (e.g., clinical trials).
Bupropion has a modest impact on glucose metabolism and may slightly improve glycaemic control in some patients. Nonetheless, regular monitoring of blood glucose is prudent, especially for individuals with type 2 diabetes.
When travelling, carry a copy of the private prescription and the original pharmacy label. Some countries may restrict importation of unlicensed medicines, so verify local regulations before departure.
Abrupt discontinuation can lead to transient mood changes, irritability, or a return of appetite. A gradual taper, reducing one tablet per week, is usually recommended to minimise these effects.
Clinical studies show an average weight loss of 5 % of baseline body weight after approximately 12-16 weeks of continuous therapy, provided the medication is combined with a reduced-calorie diet and regular physical activity.
Contrave is a prescription-only pill that combines two active ingredients-naltrexone (8 mg) and bupropion (90 mg) per tablet. The combination is intended to support weight management by acting on both appetite-control and reward pathways in the brain. In the United Kingdom, Contrave has not been licensed by the Medicines and Healthcare products Regulatory Agency (MHRA), so it is not available on the NHS or through UK pharmacies. The individual components are each approved for other indications: naltrexone for alcohol dependence and bupropion for major depressive disorder.
The therapeutic effect of Contrave relies on the complementary actions of its two ingredients:
When used together, the drugs are thought to produce a synergistic effect: bupropion stimulates POMC neurons, and naltrexone prevents the auto-inhibitory feedback that would otherwise limit this activation. The net result is reduced appetite, increased feelings of fullness, and a lower drive to seek highly palatable foods. Onset of appetite-modulating effects typically occurs within a few days, with peak pharmacodynamic activity reached after the titration phase is completed (approximately 2 weeks).
| Region | Regulatory authority | Indication | |--|-|| | United States | FDA | Chronic weight management in adults with a BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes). | | United Kingdom | Not approved by MHRA | The combination product is unavailable. Naltrexone alone may be prescribed for alcohol dependence; bupropion alone is approved for major depressive disorder. |
Because Contrave is not licensed in the UK, it cannot be prescribed within the NHS. Any use of the combination would have to occur under a Special Availability Scheme (e.g., via a private prescription) and would be considered off-label.
Bupropion, when used as a single agent (marketed as Zyban in the United States), is an evidence-based treatment for nicotine dependence. Although the combination with naltrexone has been explored in clinical trials, the data are insufficient to support routine use for smoking cessation. Current UK guidelines continue to recommend varenicline or nicotine-replacement therapy as first-line options.
Disclaimer: Using Contrave for smoking cessation is off-label and should only be considered after a thorough risk-benefit discussion with a qualified healthcare provider.
Naltrexone is approved in the UK for the management of alcohol dependence. Some studies have examined whether adding bupropion enhances outcomes, but results are mixed and not robust enough for formal recommendation.
Disclaimer: The combination has no regulatory approval for alcohol-use disorder; clinicians may consider naltrexone monotherapy where appropriate.
These events are generally mild to moderate and tend to lessen after the titration period.
| Interaction type | Example agents | Clinical implication | ||-|-| | Major | MAO inhibitors, CNS stimulants, other NDRIs, antipsychotics that lower seizure threshold | May precipitate seizures or severe hypertension; avoid concurrent use. | | Moderate | CYP2B6 inhibitors (e.g., ritonavir) or inducers (e.g., rifampin) | May alter bupropion plasma concentrations; dose adjustment may be needed. | | Pharmacodynamic | Opioid analgesics (e.g., morphine) | Naltrexone blocks opioid receptors, potentially reducing analgesic efficacy. |
Note: The titration is designed to minimise nausea and other gastrointestinal side effects. The final maintenance dose is reached after two weeks of gradual escalation.
Because Contrave is unlicensed in the UK, any prescribing would be under a private or special-access arrangement and must follow the same titration principles used in the United States.
If adverse effects arise (e.g., uncontrolled hypertension, seizure, severe mood changes), the medication should be discontinued promptly.
This article provides educational information about Contrave and is not a substitute for professional medical advice. Treatment decisions, including the use of unlicensed or off-label medications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
